Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...
Investing17m
Novo Nordisk shares spike on results from experimental obesity drug trial
Investing.com - Copenhagen-listed shares in Novo Nordisk (CSE: NOVOb) surged on Friday after the Danish drugmaker said ...
Novo Nordisk A/S: Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...
manilatimes40m
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Bagsværd, Denmark, 24 January 2025 - Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with ...
manilatimes40m
DIDWW extends A2P SMS service to include the USA, Ukraine and Cyprus
"We are proud to expand our A2P SMS service to the USA, Ukraine and Cyprus,” commented Tadas Urbietis, Carrier Relations ...
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...